With a one year PEG ratio of 287.6, Pacira BioSciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 89.72% of US stocks.
Price to trailing twelve month operating cash flow for PCRX is currently 18.04, higher than 83.33% of US stocks with positive operating cash flow.
Revenue growth over the past 12 months for Pacira BioSciences Inc comes in at 24.83%, a number that bests 80.76% of the US stocks we're tracking.
Stocks with similar financial metrics, market capitalization, and price volatility to Pacira BioSciences Inc are AVLR, GRUB, SMAR, AXTI, and LC.
PCRX's SEC filings can be seen here. And to visit Pacira BioSciences Inc's official web site, go to www.pacira.com.
Pacira Pharmaceuticals develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company was founded in 2006 and is based in Parsippany, New Jersey.
PCRX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for PCRX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Pacira BioSciences Inc ranked in the 76th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of Pacira BioSciences Inc, consider:
Its compound free cash flow growth rate, as measured over the past 4.99 years, is 0.76% -- higher than 89.14% of stocks in our DCF forecasting set.
Pacira BioSciences Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 0.55. This coverage rate is greater than that of only 21.73% of stocks we're observing for the purpose of forecasting via discounted cash flows.
The weighted average cost of capital for the company is 9. This value is greater than 80.47% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Pacira BioSciences Inc? See CI, INVA, CCEL, CVS, and ABC.